Literature DB >> 29212122

Levels of Circulating Intermediate Monocytes Decrease after Aortic Valve Replacement in Patients with Severe Aortic Stenosis.

Bernd Hewing1,2,3, Rena Ellerbroek1, Sebastian Chi-Diep Au1,3, Verena Stangl1,3, Henryk Dreger1,3, Michael Laule1, Herko Grubitzsch4, Fabian Knebel1,2,3, Gert Baumann1, Antje Ludwig1,3, Karl Stangl1,3.   

Abstract

Aortic valve stenosis (AS) is a chronic inflammatory disease. We have previously shown that severe AS is associated with increased levels of circulating intermediate monocytes. Haemodynamics are considered to influence levels of circulating monocyte subsets; we therefore hypothesized that aortic valve replacement may result in changes in the distribution of circulating monocyte subsets. In the present study, we evaluated levels of circulating monocyte subsets in patients with severe AS undergoing surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR). Levels of classical (CD14++CD16–), intermediate (CD14++CD16+), and non-classical (CD14+CD16++) CD86-positive monocytes were determined by flow cytometry in peripheral blood of patients with severe AS before (baseline) and at 3- and 6-month follow-ups (FUP) after SAVR (n = 25 patients) or TAVR (n = 44 patients). Absolute and relative levels of circulating intermediate monocytes decreased from median 39.9/µL (interquartile range [IQR]: 31.7–53.6/µL) and 6.7% (5.6–8.1%) at baseline to 31.6/µL (24.3–42.4/µL; p < 0.001) and 5.4% (4.4–6.7%; p < 0.001) at 6-month FUP after aortic valve replacement, respectively. The decrease in levels of circulating intermediate monocytes appeared earlier (between baseline and 3-month FUP) in the TAVR group compared with the SAVR group (between 3- and 6-month FUP). In conclusion, levels of circulating intermediate monocytes decrease after SAVR or TAVR in patients with severe AS.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29212122     DOI: 10.1160/TH17-05-0341

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

1.  Digital Holographic Microscopy for Label-Free Detection of Leukocyte Alternations Associated with Perioperative Inflammation after Cardiac Surgery.

Authors:  David Rene Steike; Michael Hessler; Eberhard Korsching; Florian Lehmann; Christina Schmidt; Christian Ertmer; Jürgen Schnekenburger; Hans Theodor Eich; Björn Kemper; Burkhard Greve
Journal:  Cells       Date:  2022-02-21       Impact factor: 6.600

Review 2.  Innate immune cells in the pathophysiology of calcific aortic valve disease: lessons to be learned from atherosclerotic cardiovascular disease?

Authors:  Wieteke Broeders; Siroon Bekkering; Saloua El Messaoudi; Leo A B Joosten; Niels van Royen; Niels P Riksen
Journal:  Basic Res Cardiol       Date:  2022-05-17       Impact factor: 12.416

Review 3.  Circulating Monocyte Subsets and Transcatheter Aortic Valve Replacement.

Authors:  Fanny Lassalle; Mickael Rosa; Bart Staels; Eric Van Belle; Sophie Susen; Annabelle Dupont
Journal:  Int J Mol Sci       Date:  2022-05-10       Impact factor: 6.208

Review 4.  Uncoupling the Vicious Cycle of Mechanical Stress and Inflammation in Calcific Aortic Valve Disease.

Authors:  Nalin H Dayawansa; Sara Baratchi; Karlheinz Peter
Journal:  Front Cardiovasc Med       Date:  2022-03-09

Review 5.  New Insights into the Roles of Monocytes/Macrophages in Cardiovascular Calcification Associated with Chronic Kidney Disease.

Authors:  Lucie Hénaut; Alexandre Candellier; Cédric Boudot; Maria Grissi; Romuald Mentaverri; Gabriel Choukroun; Michel Brazier; Saïd Kamel; Ziad A Massy
Journal:  Toxins (Basel)       Date:  2019-09-12       Impact factor: 4.546

6.  Elevated circulating CD14++CD16+ intermediate monocytes are independently associated with extracardiac complications after cardiac surgery.

Authors:  Jana C Mossanen; Tobias U Jansen; Jessica Pracht; Anke Liepelt; Lukas Buendgens; Christian Stoppe; Andreas Goetzenich; Tim-Philipp Simon; Rüdiger Autschbach; Gernot Marx; Frank Tacke
Journal:  Sci Rep       Date:  2020-01-22       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.